Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Buck Institute and Biotica Investigate Polyketides in Extension of Healthy Lifespan

15.09.2011
The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging.

Building on observations that rapamycin extends healthy lifespan in various species (Kaeberlein & Kennedy; Nature 2009), the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.

“We welcome this collaboration with Biotica with great enthusiasm. Their polyketides represent some of the most novel and promising drug leads for the development of therapeutics for age-related disease,” said Buck Institute CEO and President Brian Kennedy, PhD, who added that several Buck laboratories will be involved in the screening process. “We look forward to working with Biotica to move potential therapeutics toward commercialization. We have great respect for the company and their technology - the fact that we will both benefit from commercialization of new discoveries is a harbinger of great things to come.”

“Prof. Kennedy and the Buck Institute are recognized as leaders in research on aging, and have played a key role in identifying the life-extending properties of rapamycin,” commented Barrie Wilkinson, PhD, Biotica’s VP of Research. “We’re extremely fortunate to be working with the Buck’s outstanding investigators, and to have access to their diverse range of scientific approaches to age-related disease.”

The collaboration builds upon an existing relationship between Prof. Kennedy and Biotica, studying longevity-enhancing properties of non-rapamycin polyketides. The recent return of Biotica’s rapamycin analog program from Pfizer, in August 2011, has created an opportunity to add value in addition to its current focus on multiple sclerosis (MS) and systemic lupus erythematosus (SLE). In addition to the work on rapamycin analogs, the collaborators expect to identify new polyketides with therapeutic potential in age-related disease.

About the Buck Institute for Research on Aging
The Buck Institute is the first freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individual’s life. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer’s and Parkinson’s disease, cancer, cardiovascular disease and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For additional information visit www.buckinstitute.org.
About Biotica Technology Limited
Biotica is a privately-held biotechnology company that discovers and develops polyketide therapeutics. It has a growing pipeline of novel therapeutic programs supported by clinical validation. These include nPT-mTOR (unique rapamycin analogs), nPT-CyP (cyclophilin inhibitors for HCV) and nPT-ery (anti-inflammatory erythromycin analogs partnered with GlaxoSmithKline). All of Biotica’s projects employ its proprietary novoPT™ technology, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit www.biotica.com.

Kris Rebillot | Newswise Science News
Further information:
http://www.buckinstitute.org

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>